Table 1.

Study characteristics.

Study	Study design	Sample size	PTSD criteria	Male %	Mean age (years)	Prazosin dosage (mg)	Treatment duration (weeks)	Outcomes
Raskind et al., 2003 [16]	Crossover	Prazosin (10)	DSM-IV	1	53	9.5	9	Overall PTSD symptoms; nightmares
Raskind et al., 2003 [16]		Placebo (10)		1	53		9	Overall PTSD symptoms; nightmares
Raskind et al., 2007 [17]	Parallel	Prazosin (17)	DSM-IV	NR	56	13	8	Overall PTSD symptoms; sleep quality; nightmares; adverse events
Raskind et al., 2007 [17]		Placebo (17)		NR	56		8
Taylor et al., 2008 [29]	Crossover	Prazosin (13)	DSM-IV	0.154	49	3.1	3	Overall PTSD symptoms; acceptability
Taylor et al., 2008 [29]		Placebo (13)		0.154	49		3	Overall PTSD symptoms; acceptability
Raskind et al., 2013 [33]	Parallel	Prazosin (32)	DSM-IV	0.813	30.0	15.6	15	Overall PTSD symptoms; sleep quality; nightmares; adverse events
Raskind et al., 2013 [33]		Placebo (35)		0.886	30.8		15
Ahmadpanah et al., 2014 [30]	Parallel	Prazosin (33)	DSM-IV	0.758	36.18	15	8	Overall PTSD symptoms; sleep quality; nightmares; adverse events
Ahmadpanah et al., 2014 [30]		Placebo (33)		0.667	34.21		8
Simpson et al., 2015 [31]	Parallel	Prazosin (9)	DSM-IV	0.60	43.5	6	8	Overall PTSD symptoms; acceptability; adverse events
Simpson et al., 2015 [31]		Placebo (12)		0.667	43.1		8	Overall PTSD symptoms; acceptability; adverse events
Petrakis et al., 2016 [32]	Parallel	Prazosin (50)	DSM-IV	0.92	44.5	16	13	Overall PTSD symptoms; sleep quality; nightmares; acceptability
Petrakis et al., 2016 [32]		Placebo (46)		0.956	43.4		13
Raskind et al., 2018 [15]	Parallel	Prazosin (122)	DSM-IV	0.961	52.3	14.8	26	Overall PTSD symptoms; sleep quality; nightmares; acceptability; adverse events
Raskind et al., 2018 [15]		Placebo (123)		0.993	51.4		26

DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, fourth edition; NR, not recorded; PTSD, post-traumatic stress disorder.